Cancer-killing virus on FDA fast track
Imugene’s share price pumped after anti-cancer virus VAXINIA was granted FDA Fast Track designation. Here are this month’s biotech winners.
Imugene’s share price pumped after anti-cancer virus VAXINIA was granted FDA Fast Track designation. Here are this month’s biotech winners.
LTR Pharma is set to join the ASX armed with a world-first nasal spray to bring relief to erectile dysfunction sufferers and spontaneity to the bedroom.
Dual-listed Euro Manganese suddenly looks in far better shape, after an injection of $US100 million in funding. Get the latest resources news here.
ASX stock 4DMedical jumped 10 per cent after inking a deal to recruit a leading global healthcare company for its push into North America.
Taylor Collison has tipped an aluminium company and creator of science-based bioactives to be big achievers. Here’s why the broker likes them so much.
Weebit Nano has passed a key barrier for tech companies, and notched an ASX first in the semiconductor field – earning its maiden revenue.
Life isn’t easy for ASX newcomers, with just seven of the 29 stocks to list this year muscling up. Here’s a look at those that lifted shareholders’ spirits.
Lithium producers may end up feeling a little salty, as battery makers look to a type of tech that doesn’t need ‘white gold’ to function.
Accelerate Resources is living up to its name, moving forward at pace after news about impressive outcroppings at its Prinsep lithium project.
Growth stocks can do exactly what the name suggests, and analysts from MA Moelis reckon this trio could be pre-Christmas gifts that keep giving.
Australia is in a tech jobs crisis and we need a national response to meet the challenge, according to the Australian Computer Society.
As M&A-loving big players seek perfect matches, they are eyeing alluring offerings in South America, with these ASX stocks looking attractive.
Firebrick’s share price surged by 100 per cent last week on news about its antiviral nasal spray, as ASX stocks chase a potentially $US90 billion market.
Chariot Corporation – up more than 370 per cent over the past month – copped a speeding ticket from the ASX … then started charging again.
In a consistently inconsistent ASX small-cap discretionary retail sector, life is difficult for investors hoping to snag a bargain, says Tim Boreham.
Momentum matters for stocks and even more, no surprise, for momentum investors. Here are the companies moving forward right now.
New, non-intrusive technology is helping surgeons – human and robot – to sharpen their focus. Tim Boreham examines the tech, and company behind it.
While the global economic outlook hasn’t been all that sunny, silver – valuable as both investment vehicle and industrial metal – is still shining.
You can love the planet – and your mining profits too. That’s the startling message BlackRock and other ESG-focused firms are sending to investors.
Rhythm Biosciences says results from a study of its potentially lifesaving lung cancer detection tech make a strong case for moving the project forward.
The Secret Broker’ takes us into the arcane world of shorting, ‘puts’ and CFDs … before asking if we should ban trading in derivatives altogether.
An IPO can be a path to profit, but before you get started, we’d better bury some myths. Then you can consider these new offerings.
Norfolk Metals says that with uranium sentiment continuing to improve, there are few exploration stocks with its combination of project, funds and tight capital structure.
The champions of hydrogen have fired a few salvos, including Toyota unveiling a vehicle using an internal combustion engine fuelled by the gas.
ASX fintechs say they are perfectly positioned to ride the AI wave, with their ‘DNA’ giving them a huge advantage over traditional bankers.
Impatient investors drove down cardiac disease specialist EBR Systems’ price by double digits on Wednesday, after a delay in key FDA approvals was announced.
Melodiol Global Health is delivering on its strategy to bring core operating subsidiaries to profitability, with Health House International generating $1 million in October.
A new high-growth fund has just made it much easier for Australians to get a foothold in the lucrative US residential property market.
Cannabis has lost its buzz a little, with progress in legal and medical acceptance slow. So these ASX firms want to show they’re not just ‘pot stocks’.
Goldman Sachs believes Webject is better placed than its peers to take advantage of the return to long-haul travel. And it’s bullish on Life360 too.
James Bay Minerals has now mapped out three lithium-rich peggies across a 2.5km stretch at its Aero property, associated with a “prominent green mineral”.
India’s banking sector is huge, with plenty of room for growth. And ASX stock Findi’s ATMs are raking in, as well as dispensing, the rupees.
Cooper Metals has been galloping along – appropriate, really, given one of the hot prospects spurring it on is Brumby Ridge. Get your resources wrap here.
Orthocell has released a study demonstrating that its tendon cell therapy OrthoATI is likely a better treatment than surgery for severe tennis elbow.
Strategic Elements says its moisture-based renewable energy tech – Energy Ink – has achieved impressive power density and now aims to provide a charge to an electric car.
Altech Batteries has increased the Silumina project DFS output eightfold to 120 GWh to produce 8000tpa of alumina-coated metallurgical silicon for the electric vehicle market.
Methane is 28 times more potent as a greenhouse gas than carbon dioxide – and landfills are releasing plenty into the atmosphere. This may be an answer.
Unveiling of a resources estimate can be a magical moment for investors and companies. These ASX miners are set to show their hands in the next six months.
The ASX small caps sector is being neglected, even though history suggests it is set to deliver strong returns, says Aussie investment management firm Datt Capital.
Talk about a joy story! Infinity Lithium has won $31 million in Spanish government funding for its San Jose project – driving INF shares higher.
Medtech company 4DMedical put on a mighty surge after a key US federal agency agreed to cover its lung scanning device – at $US299 a pop.
The prospect of arbitrage-fuelled profit is enough to make The Secret Broker cry out ‘c’est magnifique’, probably in a Monty Python-like outrageous accent.
Seeing a stock shining in one of these three key metrics brings a warm glow to the hearts to momentum investors. Here’s this week’s heads-up.
Resources fund portfolio manager Ben Cleary explains why a trio of themes will drive mining and energy sectors forward in 2024, and nominates his top stock picks.
China’s tightening of graphite export rules is set to re-energise the industry elsewhere, driving up prices and lifting shares, say these four ASX stocks.
As the economy tightens, folks seem to want to let loose on holidays. Enter, Camplify, which shifts up a gear when times get tough. Tim Boreham explains.
In a significant development on the clean energy frontier, Pilot Energy and Samsung have joined forces through a non-binding MoU to spearhead WA’s Mid West Clean Energy Project.
Regenerative medicine biotech, AVITA Medical jumped 24 per cent after providing attention-grabbing guidance for Q4 FY23. Here’s your health wrap.
Bailador Technology Investments reckons the largest position in its portfolio, SiteMinder, is poised to unlock a huge upside by adding key functionality for hotels to increase revenue.
Market Matters lead author James Gerrish is feeling less bullish these days, predicting interest rate cuts and rising hopes. Here’s his analysis and stock tips.
Original URL: https://www.heraldsun.com.au/business/stockhead/page/47